Samantha Peacock

Samantha’s experience includes advising:

Venture Capital - Investor Side

• atai Life Sciences on its strategic investment in Beckley Psytech, a private clinical-stage biotechnology company
• Patient Square Capital on its US$226.5m lead investment in Apollo Therapeutics’ Series C financing round
• Octopus Ventures on multiple investments including in Menwell (t/a Manual), Pencil Biosciences, Vira Health, Awell Health, and Touchlab spanning from pre-seed to Series B
• Hoxton Ventures on its lead investments in Skin Analytics, Bother, Slice, and Luminary ROLI
• Novo on its Series E and D investment s in Quanta Dialysis Technologies, a commercial-stage dialysis device company
• Citi Ventures on its investment in GoHenry’s US$40 million funding round
• GIC, JP Morgan, and HSBC’ Venture Capital Fund on their Series B+ investments in Miotech, an ESG data start up

Venture Capital - Company Side

• OrganOx, a leading organ medical technology company, on its US$142m primary and secondary equity financing round led by HealthQuest Capital, BGF and Lauxera Capital Partners
• Verdiva Bio, a clinical-stage biopharmaceutical company, on its US$410m Series A financing, led by Forbion and General Atlantic
• WorldRemit on its US$292m Series E funding round
• Toqio on its seed funding round led by Seaya and Speedinvest
• LifeScore on its £11m Series A financing led by Octopus Ventures and Warner Music Group
• Aztec Network on its Series B and A funding round s led by a16z and Paradigm respectively
• Fertifa Limited, the UK’s first and leading reproductive healthcare benefits provider and provider of a next-generation fertility clinic, on its seed funding round led by Passion Capital

Healthcare & Life Sciences M&A

• BC Partners on its agreement to sell a majority stake in Synthon, a leading international pharmaceutical company, to Goldman Sachs Alternatives
• Novo Holdings on its agreement to acquire the Norwegian fish genetics company Benchmark Genetics from Benchmark Holdings plc
• Norgine, a European specialty pharmaceutical company, on the sale of a controlling stake to Goldman Sachs Asset Management
• Lindsay Goldberg on the acquisition by its portfolio company, MMS, A CRO of data science company Exploristics
• TPG on its acquisition of Doc Generici, a leading Italian generics company
• Alliance Pharma on its acquisition of US scar treatment brand, ScarAway
• Acino on the acquisition of approximately 30 products across Takeda’s primary care portfolio in MENA and Ukraine
• Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the US$703 million acquisition by CVC of women’s healthcare assets from Teva 
• TLS Beta on the acquisition of a 30% stake in Stamford Devices, an Ireland-based provider of medical device and drug delivery services and holding company for Aerogen 
• Actavis UK and Actavis Ireland on its £603 million divestment by Teva to Intas* 
• Actavis on its £306 million acquisition of Auden Mckenzie, a pharmaceutical company specialising in the development, licensing and marketing of generic medicines and proprietary brands, making Actavis the largest generics company in the UK
• Actavis on the divestment of part of its Western European generics sale and marketing business to Aurobindo*

M&A

• CDPQ on its partnership with GIM and joint investment in FNZ, a deal valuing the company at £1.65 billion and being one of the world’s largest fintech transactions of 2018
• Thomas Cook on the sale of its Belgium airline business to Brussels Airlines, a subsidiary of Lufthansa
• H&F on the disposal of a minority interest in the Verisure Securitas Direct group to GIC
• Onex on its up to €3.75 billion acquisition of SIG Combibloc Group AG

*Matter handled prior to joining Latham